Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System
International Journal of Dermatology · 2026-01 · 65 (1) · 108-118
DOI: 10.1111/ijd.17957 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Dermatology, online erschienen am 15.07.2025. Verfasst von Aditya K Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Finasteride, 5-alpha Reductase Inhibitors, Alopecia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation. These AEs are controversial and often lack assessment of contributing risk factors. We analyzed FDA Adverse Event Reporting System (FAERS) data to explore finasteride's administration route and PFS‐like AEs.
Methods
Using the information component (IC) method for disproportionality analyses, we assessed signals for 13 PFS‐related AEs with topical and oral finasteride and dutasteride across two periods: 2006–2011 (pre‐PFS reporting) and 2019–2024 (post‐PFS reporting). These periods reflect times before and after formal PFS reporting in 2012. Eight analyses per AE were conducted based on agent, route, and era.
Results
Fewer signals for PFS‐like AEs were detected with topical finasteride compared to oral finasteride in both eras. No signals were found for topical dutasteride, possibly because its use is very limited. Many reported AEs, such as erectile dysfunction and depression, may be influenced by age, stress, or comorbidities.
Conclusions
Signals for PFS‐like AEs were detected with topical finasteride, but were less frequent than with oral finasteride. The high prevalence of these AEs in the general population and the influence of confounding factors, such as psychological stress or nocebo effects, combined with the lack of genotyping, hormonal assessments, or family history data in most reports, suggest caution in attributing causality to finasteride. Topical finasteride may pose a lower risk, but robust evidence is needed to clarify its safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- School of Pharmacy, BRAC University, Dhaka, Bangladesh.
- Physician's Hair Institute, Tucson, Arizona, USA.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder, Mary A Bamimore
Zitieren
APA
Gupta, A. K., Talukder, M., Keene, S. A., & Bamimore, M. A. (2026). Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. International Journal of Dermatology, 65(1), 108-118. https://doi.org/10.1111/ijd.17957
Vancouver
Gupta AK, Talukder M, Keene SA, Bamimore MA. Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. International Journal of Dermatology. 2026;65(1):108-118. doi:10.1111/ijd.17957
BibTeX
@article{Gupta2026,
author = {Gupta, Aditya K and Talukder, Mesbah and Keene, Sharon A and Bamimore, Mary A},
title = {Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {1},
pages = {108--118},
doi = {10.1111/ijd.17957}
}
EUVIMED